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Email: Dan@b-alert.com 7 provide a means to synchronize the PSG and the NPTD records, subjects were instructed to sit upright in bed for one-minute just prior to lights out and just after lights on. Technicians were instructed to attempt to acquire equivalent amounts of supine and non-supine sleep from each subject.
For the position therapy period, subjects were instructed to wear the NPTD for 30-nights while in bed and attempting to sleep. The first two nights provided an adaptation period in which no feedback was delivered. This allowed participants the opportunity to withdraw prior to initiating 28 consecutive nights of NPTD therapy and being categorized with an intention to treat. Subjects maintained daily logs so that potential interruption to their day-or night-time quality of life attributed to the position therapy could be evaluated, and comparisons between self-reported use and compliance measured with the NPTD could be compared. To remain in the study, subjects were required to generate a compliance report on the NPTD web-portal and mail the daily logs at the end of each week. Upon completion of four weeks of therapy, subjects completed the post-treatment battery of questionnaires and continued to receive positional therapy until completion of the follow-up PSG.
Polysomnography:
All subjects were recruited from and studied at an American Academy of Sleep Medicine (AASM) accredited sleep center (Complete Sleep Solutions, Murrieta, CA). The baseline and follow-up PSG studies were conducted and scored according to the AASM criteria. 13 Scoring of apneas required a 10-second cessation in breathing. Hypopneas required at least a 30% reduction in airflow combined with a 4% hypopnea desaturation. Subjects were studied in one of four rooms; two were equipped with obtained from the chest transducer and confirmed by video (i.e., video/chest) was used for the PSG report, and technician notes were used to identify periods when the chest was supine but the neck was non-supine left/right (i.e., head was turned and neck elevated >30 o from horizontal toward a lateral position).
Description of the NPTD:
The battery-powered NPTD (Night Shift TM , Advanced Brain Monitoring, Carlsbad, CA) weighs 44 grams and includes electronics housed in a 5.5 (l) x 3.8 (w) x 1.6 (h) cm enclosure affixed on the back of the neck with an adjustable non-latex silicone rubber strap secured by a magnetic clasp (see Fig 1) . 14 The NPTD measures snoring with a built-in, calibrated acoustic microphone. The raw audio input is sampled at 2 kHz, and root mean square (RMS) of the digitized signal is calculated using a 100 ms window. The resulting 10 Hz RMS signal is additionally filtered with a 0.5Hz low-pass Butterworth 4 th order filter. A snore detection algorithm quantifies each snore based on the shape and the peak amplitude, prior to conversion to decibels (db). Loud snoring is defined as at least one snore with a magnitude > 50 dB in a 30-second epoch. The percentage of time snoring >50 dB is then determined for overall, supine, and non-supine epochs characterized as sleep by the NPTD. . If the NPTD is worn upside down, the supine position will be accurately determined; however reported time in the lateral left and right will be reversed. Thirty-second epochs are classified as sleep or wake by comparing the median filtered output derived from the three X, Y, and Z signals to a fixed threshold. If any of the three signals have an angle <50 O and exceed the actigraphy threshold, the epoch is classified as wake. In addition, long periods with gross movement extend the wake classification for up to three subsequent 'silent' epochs. The initial ten-minute period after the NPTD is turned on is automatically classified as wake.
Two x 1G haptic motors provide vibro-tactile feedback when the supine position is detected.
Positional feedback is modulated by setting the number of motors to be excited (one or both) and varying the duration of the motor(s) excitation. Feedback is initiated at a very low frequency/duration, and gradually increased until the user exits the supine position. At any given intensity level, the feedback is repeated three times with an inter-feedback interval of two-seconds. The feedback can be optionally paused for a pre-defined time interval or completely turned off. A total of seven levels of feedback are delivered with levels five through seven utilizing both haptic motors. For this study vibrotactile feedback was defaulted to initiate 15-minutes after the NPTD was turned on, to allow the user time to fall asleep. Upon conclusion of an upright period > 45-seconds, positional feedback was paused To assess position therapy compliance, the utilization rate was defined as the number of nights that the device was worn for a minimum of four hours divided by the days during the intention to treat period, similar to that used for CPAP. 15 
RESULTS:
Thirty-six subjects were initiated into the study. All but one subject wore the NPTD during their baseline study. Five subjects were dropped as a result of their baseline PSG results. Two had very severe sleep disordered breathing with an overall to non-supine ratio < 1.5, two had an overall AHI <5, and one had <4-hours of sleep time. One subject was dropped for protocol non-compliance due to failure to maintain and submit daily sleep diaries. Of the 22 males and eight females who completed the protocol, 37% had mild overall OSA severity (AHI >5 and <15), 33% had moderate overall severity (AHI >15 and <30), and 30% had overall severe OSA (AHI >30).
Primary Endpoints:
Respiratory Measures: Based on effectiveness of the supine sleep restriction, the overall and supine AHI, apnea index, and percent time SpO2 < 90% were significantly reduced (Table 1) . Across all participants, the mean percent reduction in AHI was 69% and the median reduction was 79%. At follow-up, 73%
percent of participants achieved an AHI < 10 with a >50% reduction in overall AHI, and an additional 17%
showed potentially important reductions in overall AHI of 50% or 35% (Table 2 ). Three non-responders exhibited > 60% increase in non-supine AHI at follow-up. Subjective Measures: The impact of four-weeks of position therapy on subjectively measured impairment and quality of life are presented in Table 4 . Subjects showed a significant improvement in depression scores, and marginally significant improvements in ESS, POMS and ISI.
Secondary Endpoints:
Supine Detection: The NPTD measures of the percent of recording time spent in the supine position were in close agreement with the percent of time supine determined by video inspection of the 29 baseline and 30 follow-up studies (Fig. 2) . For the baseline PSG records, three cases had an absolute difference between neck supine and chest plus video supine >5%. For the follow-up studies, NPTD estimates were within 5% of values based on the chest sensor plus video in 28 of 30 studies. Larger disagreements between the PSG and NPTD estimates occurred in patients who spent a portion of the night with the head turned far to the side while the torso was supine. Incorrect detection of supine sleep which would result in non-delivery of therapy for >5% of sleep time was limited to 2 of 59 cases
Sleep/Wake Detection: Table 5 presents the mean sensitivity (sleep) and specificity (wake) of neck actigraphy as compared to PSG. Significant improvements in overall accuracy were observed during the follow-up PSG when positional feedback was delivered.
Differences in total sleep time (TST), sleep efficiency (SE), sleep onset (SO) and wake after sleep onset (WASO) are presented in Bland-Altman plots ( Figure 4) . No statistically significant differences between PSG and NPTD were observed during either the baseline or the follow-up for TST, SE, SO and WASO. Variability about the mean was reduced by over one-third for TST, SE and WASO when therapy was delivered during the follow-up PSG.
Supporting Evidence:
NPTD Home Use: Across subjects, the device was worn in 99% of the possible treatment nights with a median compliance rate of 96% (range 71 to 100%). Twenty-seven of 30 subjects maintained the nonsupine position over more than > 98% of the time across nights of use; the remaining three spent 96%, 93% and 84% of the time in bed in the non-supine position. The mean number of supine attempts per night trended lower across the four weeks of treatment but no consistent pattern suggesting a training effect was apparent. Most did not require delivery of the maximum feedback intensity (i.e., max alert)
to change positions. The participants were in general not awakened by the feedback, as they recalled only one third of all stimuli delivered (median: 2; range 1 -4). Repeated measures ANOVA showed that the compliance measures did not significantly vary throughout the four weeks of treatment ( Table 5 ).
The average number of perceived stimuli per night also did not change over time.
How the NPTD was adjusted for larger necks may have influenced how often it fell off during the night. Twenty subjects reported the NPTD remained in place during sleep without incident across the four weeks of therapy (neck size 39 + 3.8 cm). Two reported the device fell off once, and six subjects reported the NPTD fell off between two and four times (neck sizes ranged from 39 to 45.7 cm). One subjects with a neck circumferences of 44 cm reported the device fell off nine times in the first two weeks and 11 times overall. Another subject with a neck circumference of 44.5 cm reported the device fell off 12 times in weeks three and four, and a total of 16 times.
In total, six patients reported symptoms of minor back, shoulder, or neck discomfort in the morning across two or more weeks of therapy. Of these, one subject identified noticeable/extreme back, shoulder, or neck pain across the first two weeks of therapy. A second participant experienced noticeable/extreme pain during week three. All remained in the study until completion.
Across all subjects and nights, the percentage of occurrences that perceived sleep quality was worse/substantially worse as a result of Night Shift trended downward from 13.4% in week 1, 10.2 in week 2, 9.5% in week 3, and 7.4% in week 4.
Prevalence of POSA: Of the 363 PSG reports available for the retrospective analysis, 26 (7%) had an AHI <2 and 128 (35%) had less than 20 minutes of sleep time in either supine or non-supine position; thus, a total of 209 reports were ultimately used for the assessment of POSA prevalence. Table 6 presents the prevalence distributions stratified by and across OSA severities, with the accompanying group AHI distributions. The prevalence of POSA was consistently > 70% across all severity categories, other than those with very severe OSA (the AHI was <60 in over 80% of the studies). Additional statistical analyses showed no evidence of a significant relationship in this sample between the presence/absence of POSA and variables such as age, BMI, total sleep time or total time spent in the supine position.
DISCUSSION:
Several recent studies demonstrated success with supine avoidance therapy when enrollment was limited to mild and moderate OSA. It is difficult to explain why significant improvements in sleep architecture and sleep continuity only contributed to modest improvements in subjective scores. Applying an ESS change > 2 as a clinically relevant threshold, subjective sleepiness did not increase in any of the study participants, 83%
of those with an ESS <7 and 73% of those with an ESS >13 reported an improvement. However only 15%
with an ESS between 8 and 12 reported ESS improvements of 2 or more. Of the six subjective measures we evaluated, the FOSQ showed the least statistical improvement. A moderate association was observed between the ESS and depression change scores (r=0.63, p< 0.001).
In a comparable study, Van Mannan 10 found no significant differences in the PSG-derived data but noted significant improvements in ESS and FOSQ responses after 30-days of position therapy. In both studies, 50% of participants exhibited an ESS improvement of 2 or more. In the Van Mannan cohort, the ESS improvements were more equally distributed across ESS ranges. Differences in the two studies with respect to improvement of the FOSQ are difficult to explain other than patients living in Southern California reported improved quality of life scores before and after the study, with less group variability, than those living in the Netherlands.
Of the three subjects who were totally non-responsive to the NPTD, night to night variability in post-treatment AHI 17, 18 was likely a contributing factor in two cases. Both subjects exhibited > 60% increase non-supine AHI compared to baseline, yet reported substantial improvements in FOSQ and other subjective scores, after four weeks of position avoidance therapy. Given these findings, it would be beneficial to cross-validate the NPTD with a sham controlled study in a larger, more diverse population.
Ten percent of the subjects in this study slept greater than 5% supine when supine-avoidance feedback was delivered; as compared to 29% for the Van Maanan cohort. 10 This discrepancy is likely attributed to differences in the two approaches used for delivery of supine avoidance feedback. The NPTD will not initiate feedback for 15-minutes after the device is turned on and for five minutes after any sustained upright period greater than one-minute. The chest-device delays feedback for 30-minutes after being turned on, and again for 30-minutes after any sustained upright time. The occurrences of false-negative delivery of vibro-tactile therapy (i.e., percent supine errors greater than 5%) were similar for the NPTD (i.e., 2 of 59 cases) and torso supine sleep reported by Bignold et al. 11 (i.e., 1 of 15 cases).
In all three studies, subjects were accepting of vibro-tactile feedback and compliant in its use. The definition of POSA used in this study was selected as a result of the FDA requirement that the NPTD demonstrate a 50% reduction in overall AHI. The classic definition of POSA (i.e., supine AHI at least two times greater than the non-supine AHI), does not consider the impact of supine sleep time and/or supine AHI severity in its contribution to the overall AHI. Rather than create a sophisticated algorithm to screen for various combinations of supine AHI severities and durations, we utilized an alternative criteria whereby the overall AHI had to be at last 1.5 times greater than the non-supine AHI for our enrollment. To demonstrate these alternative criteria did not bias the results, we compared the two POSA definitions using the data provided in Table 6 . The net difference was to reclassify six percent of patients with an AHI < 15 (8 of 132), and 2% of patients with an AHI > 15 as non-positional vs. the classic definition of POSA. This does, however, suggest the NPTD would likely be much less useful for OSA patients who already have the habit of sleeping in the non-supine position. In retrospect, the classic definition of POSA 2,6,10 is preferable so long as the contribution of the supine sleep disordered breathing on the overall AHI is considered in combination with the selected SpO2 desaturation criteria. As compared to a 4% desaturation, a 3% reduction in oxyhemoglobin desaturation will result in a greater number of hypopnea events being identified. If the increase in non-supine events occurs at a greater rate than supine events, then alternative definitions of POSA may be necessary.
Using the classic definition, POSA prevalence at our study site was approximately 5% greater than previous reports. 1, 3 The percentage of patients with POSA and mild OSA was identical to Benoist 5 (72.9 vs. 73.3%, respectively), and very close for moderate OSA (74.1% and 78.1%, respectively). We chose to evaluate the POSA prevalence with severe and very severe OSA and found that POSA was distributed quite similarly across all AHI severities < 60. When our severe and very severe OSA groups were combined, the POSA prevalence for those with an AHI > 30 was greater than for Benoist (41.1% vs.
30.0, respectively). The percentage of PSG studies which could not be classified due to insufficient supine or non-supine sleep time was equivalent to another POSA prevalence report. 3 Unfortunately, due to the overwhelming directive toward CPAP therapy, it is common for OSA diagnostic studies to be conducted with an insufficient assessment of positional severity. In some cases, home sleep testing devices are used that do not measure position, 20 and in other cases split-night PSG studies are performed with insufficiently recorded amounts of supine or non-supine sleep time. 3 Given the influence positional severity has on outcomes across all OSA therapies, 2, 21 it raises the question as to why the adequate characterization of positional OSA severity is an option, rather than a requirement, for the delivery of an acceptable OSA diagnostic study.
A BMI < 35 was used an inclusion criteria as a precaution for potential neck and shoulder problems that might have resulted from increased non-supine sleep in those morbidly obese. Several of the studied subjects complained of minor shoulder or neck soreness as a result of increased non-supine sleep; however the discomfort was insufficient to withdraw from the study. A post-hoc analysis confirmed there was no relationship between increased BMI and complaints of discomfort. Although the BMI criteria resulted in exclusion of a quarter of potential candidates from the study site, an analysis of the POSA prevalence data stratified for BMI > 35 suggested greater bias toward non-positional OSA, although the sample size of high BMI individuals (n=53) was small. Because supine avoidance feedback is delivered to the neck rather than the torso, there is no obvious reason why an obese POSA patient would not be effectively treated with the NPTD. Additional investigations are needed to evaluate efficacy and potential side effects with the NPTD used on larger patients. Additionally, it may be useful to develop a questionnaire to help identify patients with histories of neck or back issues that might be exclusion criteria for position therapy.
In this study, 45% of those with mild OSA, 11% with moderate OSA and 56% with severe OSA had at least a 10% reduction in the frequency of loud snoring. The significant reduction in loud snoring (defined as at least one snore in a 30-second epoch > 50 dB) reported in this study conflicts with Bignold et al. report that supine avoidance does not reduce snoring. 11 Differences in the characterization of loud snoring (i.e., 50 dB vs. 70 dB) were likely attributed to differences in the measurement with an acoustic microphone at the neck vs. nasal prongs. The NPTD automatically excluded loud sounds acquired when actigraphy-based wake or upright times which were likely equivalent to the hand scoring of intensity employed by Bignold. The finding that over half of the patients with an apnea index < 10 exhibited an important reduction in snoring was consistent with Ravesloot's conclusion. 2 Given that changes in loud snoring may be most useful in assessing the benefit of supine avoidance therapy in benign snorers, additional studies should be conducted to evaluate the benefit of position therapy in those who exhibit insufficient sleep disordered breathing during their diagnostic study to qualify for healthcare system provided OSA therapy.
The NPTD sensitivity to the detection of sleep improved slightly and its specificity with respect to detection of wake improved considerably during the follow-up PSG when subjects were delivered supine avoidance therapy. It is common for Bland-Altman plots comparing actigraphy to PSG to distribute most of the results above the zero line, indicating the bias toward over-reporting of sleep.
Differences between NPTD and PSG were equally distributed above and below the zero line for TST, SE, and WASO. The initial under-reporting of SO was a result of automatic assignment of wake to the first 10 minutes after the device is turned on.
One of the important advantages of the NPTD, as compared to pillow-based position therapy devices, is the capability to monitor compliance and efficacy. Based on the percent time supine, number of supine attempts/night, number of times maximum feedback was required, and the average response to feedback, these data suggest subjects do not acclimate and become non-responsive to vibro-tactile feedback. These findings suggest, but do not definitively prove, the treatment outcomes were a result of the therapeutic impact of the device and not a training/behavioral effect. We found that those who responded slowly to feedback remained slow responders across the treatment period.
To overcome one of the limitations of this study, an evaluation is underway to assess long term compliance with the NPTD. This study will allow us to assess changes in subjective measures and compliance across a six-month observation window. This study will also allow us to evaluate whether one can become behaviorally trained to avoid the supine position without feedback, 22 or if position therapy will need to be delivered nightly to be effective, as with other OSA treatments. Another study is 21 underway to evaluate the benefit of positional therapy in combination with sub-optimal outcomes resulting from oral appliance therapy.
It is often presumed that that CPAP should be offered as the initial treatment option across all OSA severity ranges and only patients with mild to moderate sleep disordered breathing who are noncompliant with CPAP are candidates for a position therapy (or other non-CPAP treatment). To challenge this conventional thinking, a randomized trial is required with control groups having either NPTD or CPAP. Endpoints based on utilization and subjective outcomes would be justified based on the assumption that a treatment that is 60% effective and used 100% of the time by a majority of patients may be more useful than a treatment that is 100% effective but used only 40% of the time by only half of the patients. The results from such a study, in combination with better profiling of patients during the diagnostic study, might contribute to adoption of a wider range of initial treatment options or combinations of therapy, and improved long-term outcomes. 
